AR095143A1 - Dispersión sólida que comprende cilostazol amorfo y proceso de preparación - Google Patents

Dispersión sólida que comprende cilostazol amorfo y proceso de preparación

Info

Publication number
AR095143A1
AR095143A1 ARP140100366A ARP140100366A AR095143A1 AR 095143 A1 AR095143 A1 AR 095143A1 AR P140100366 A ARP140100366 A AR P140100366A AR P140100366 A ARP140100366 A AR P140100366A AR 095143 A1 AR095143 A1 AR 095143A1
Authority
AR
Argentina
Prior art keywords
solid dispersion
amorfo
preparation process
cilostazol
includes cilostazol
Prior art date
Application number
ARP140100366A
Other languages
English (en)
Inventor
Kawasaki Junichi
Nakamura Atsuya
Kamada Naoki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR095143A1 publication Critical patent/AR095143A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Reivindicación 1: Una dispersión sólida que comprende (i) cilostazol y (ii) un copolímero de ácido metacrílico S y/o un copolímero de ácido metacrílico L, caracterizada porque el cilostazol está disperso en un estado amorfo en el copolímero de ácido metacrílico.
ARP140100366A 2013-02-06 2014-02-04 Dispersión sólida que comprende cilostazol amorfo y proceso de preparación AR095143A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013021475 2013-02-06

Publications (1)

Publication Number Publication Date
AR095143A1 true AR095143A1 (es) 2015-09-30

Family

ID=50184966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100366A AR095143A1 (es) 2013-02-06 2014-02-04 Dispersión sólida que comprende cilostazol amorfo y proceso de preparación

Country Status (12)

Country Link
US (1) US9555026B2 (es)
EP (1) EP2953615B1 (es)
JP (2) JP5980449B2 (es)
KR (1) KR102205192B1 (es)
CN (1) CN105050586B (es)
AR (1) AR095143A1 (es)
AU (1) AU2014215920B2 (es)
CA (1) CA2899389C (es)
HK (1) HK1218618A1 (es)
PH (1) PH12015501722B1 (es)
TW (1) TWI615157B (es)
WO (1) WO2014123244A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019016400A2 (pt) * 2017-02-10 2020-04-07 Altum Pharmaceuticals Inc composições de complexos de gálio (iii) para administração oral
KR102114550B1 (ko) * 2018-07-10 2020-05-22 삼육대학교산학협력단 생리학적 체내 동태 연구 모델링을 이용한 약제학적 조성물의 제조 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007217A1 (fr) 1991-10-01 1993-04-15 Otsuka Pharmaceutical Factory, Inc. Resine, tube, film et revetement antithrombotiques
JP3799093B2 (ja) * 1995-01-10 2006-07-19 大塚製薬株式会社 樹脂粒状物およびこれを含有する医療製剤
WO1996021448A1 (en) 1995-01-10 1996-07-18 Otsuka Pharmaceutical Co., Ltd. Resin particle, medical material and pharmaceutical preparation containing said resin particle
PT784974E (pt) 1995-07-26 2003-09-30 Kyowa Hakko Kogyo Kk Preparacao de derivados de xantina numa dispersao solida
JPH11246404A (ja) 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
ATE461700T1 (de) * 2002-12-20 2010-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
CN1241566C (zh) * 2004-03-15 2006-02-15 深圳海王药业有限公司 西洛他唑固体分散体及其片剂制备方法
JP2008521878A (ja) 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
SG2014009252A (en) 2005-12-22 2014-05-29 Otsuka Pharma Co Ltd Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
US20110165236A1 (en) 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
KR20080076440A (ko) * 2007-02-16 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
EP2155166A2 (en) 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
BRPI0817822A2 (pt) 2007-10-19 2015-03-31 Otsuka Pharma Co Ltd Preparação sólida farmacêutica do tipo matriz
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
TW201010743A (en) 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
WO2011027656A1 (en) 2009-09-04 2011-03-10 Semiconductor Energy Laboratory Co., Ltd. Transistor and display device
KR101282847B1 (ko) 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
HK1218618A1 (zh) 2017-03-03
KR20150115859A (ko) 2015-10-14
CA2899389C (en) 2021-02-16
KR102205192B1 (ko) 2021-01-20
US20150366859A1 (en) 2015-12-24
CA2899389A1 (en) 2014-08-14
CN105050586A (zh) 2015-11-11
EP2953615A1 (en) 2015-12-16
AU2014215920B2 (en) 2018-03-15
JP2016506948A (ja) 2016-03-07
AU2014215920A1 (en) 2015-08-20
WO2014123244A1 (en) 2014-08-14
CN105050586B (zh) 2017-12-08
TW201440814A (zh) 2014-11-01
US9555026B2 (en) 2017-01-31
JP5980449B2 (ja) 2016-08-31
EP2953615B1 (en) 2018-05-23
TWI615157B (zh) 2018-02-21
PH12015501722A1 (en) 2015-11-09
PH12015501722B1 (en) 2015-11-09
JP2016193915A (ja) 2016-11-17

Similar Documents

Publication Publication Date Title
MX2021004479A (es) Agentes biologicos y su uso en plantas.
TWD185242S (zh) 集成的通用串行總線裝置延長線
EP4286104A3 (en) Robotic device with compact joint design and related systems and methods
EA201591761A1 (ru) Композиции на основе наночастиц
TWD171584S (zh) 自動出入閘門
TWD165710S (zh) 電連接器
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
TWD178855S (zh) 電連接器
CL2017000927A1 (es) Dispersiones acuosas estables de zinc fosfato
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
TWD173859S (zh) 電連接器
TWD172410S (zh) 電連接器
EP3376570A4 (en) Negative-electrode active material for electrical device, and electrical device in which said material is used
AR095143A1 (es) Dispersión sólida que comprende cilostazol amorfo y proceso de preparación
BR112015023609A2 (pt) método e sistema para transferir configurações de usuário para outro dispositivo de recebimento de usuário
UY34890A (es) Formulación acuosa altamente concentrada que comprende un plaguicida aniónico y una base
UA114776U (uk) Полімерна композиція
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
TWD174083S (zh) 電連接器之部分
TWD167929S (zh) 電連接器
SG10201903689QA (en) Devices having a housing and a foot
TWD186746S (zh) 破碎機
UA97535U (xx) Сорбційно-фільтруючий матеріал
TWD177184S (zh) 電連接器
TWD177185S (zh) 電連接器

Legal Events

Date Code Title Description
FB Suspension of granting procedure